Neuroprotection of Memantine and Rosuvastatin

Inclusion criteria * Age above 18 years old for both gender . * Adequate baseline hematologic values (absolute neutrophil count ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L and hemoglobin level ≥ 10 g/dl). * Patients with adequate renal function (serum creatinine \< 1.5 mg/dl or creatinine clearance ˃ 45 mL/min). * Patients with adequate liver function (serum bilirubin \< 1.5 mg/dl). * Patients with performance status \<2 according to Eastern Cooperative Oncology Group (ECOG) score. * Patients who will be scheduled to receive modified FOLFOX-6 or XELOX regimen. * Patients with histologically confirmed diagnosis of stage III or stage IV colorectal cancer. Exclusion criteria: * Children \< 18 years old. * Prior exposure to neurotoxic chemotherapy (oxaliplatin, cisplatin, vincristine, paclitaxel, or docetaxel, INH). * Patients with diabetes and other conditions that predispose to neuropathy as hypothyroidism, autoimmune diseases, hepatitis C. * History of known allergy to oxaliplatin or other platinum agents. * Patients with other inflammatory or stressful conditions. * Concomitant use of multivitamins (vitamins E, C, A), tricyclic antidepressants, other neuro-protective medications (gabapentin, lamotrigine, carbamazepine and phenytoin). * Patients on amantadine , acetazolamide, dextromethorphan, aluminum hydroxide magnesium hydroxide and febuxostat . * Concurrent active cancer originating from a primary site other than colon or rectum. * Pregnant and breastfeeding women. * Sever renal insufficiency (creatinine clearance \< 25 ml/ minute) .